Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLOVAGE vs ALCAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
Not applicable (non-absorbed, gut lavage); systemic absorption minimal
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Polyethylene glycol 3350 is not absorbed systemically; no hepatic metabolism.
Hydrolyzed by plasma esterases.
Primarily fecal as unabsorbed drug; negligible renal excretion (<5%)
Renal excretion of parent drug and metabolites: <5% unchanged.
Not applicable (minimal systemic absorption)
Minimal; <5% bound to plasma proteins.
Not applicable (limited to gastrointestinal tract)
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Oral: <0.3% systemically absorbed
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Contraindicated in GFR <30 m L/min/1.73 m²; for GFR 30-60 m L/min/1.73 m², use with caution due to risk of electrolyte imbalance, no dose adjustment recommended.
No dose adjustment required; negligible systemic absorption.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential fluid and electrolyte disturbances.
No dose adjustment required; negligible systemic absorption.
Not indicated for patients under 18 years of age; no established weight-based dosing.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
No specific dose adjustment, but monitor for electrolyte disturbances, dehydration, and aspiration risk; consider split-dose regimen or lower volume if tolerated.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, seizures) in patients with impaired renal function, dehydration, or those taking medications affecting electrolytes.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Monitor for fluid and electrolyte disturbances, especially in elderly, debilitated, or renal impaired patients. Use with caution in patients with gastrointestinal obstruction, ileus, or severe colitis.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis or megacolon, hypersensitivity to any component.
Hypersensitivity to any component of the formulation.
Only clear liquids (e.g., water, clear broth, black coffee/tea, clear juices) are allowed during bowel preparation. Avoid all solid foods, dairy products, red or purple liquids, and alcohol. Do not consume any food containing pulp or seeds.
None known.
Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Due to lack of systemic absorption, excretion into breast milk is negligible. Colovage is considered compatible with breastfeeding. M/P ratio: not applicable.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
No dose adjustment necessary; pharmacokinetics unchanged as drug is not absorbed.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
COLOVAGE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is a high-volume colon cleansing preparation. Ensure adequate hydration before, during, and after use. Monitor for electrolyte disturbances in patients with renal impairment or those taking diuretics. Split-dose regimen improves tolerance and cleansing quality. Avoid use in patients with gastrointestinal obstruction, perforation, or toxic megacolon.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Follow the split-dose regimen exactly as prescribed to achieve optimal bowel cleansing.,Drink additional clear liquids as directed to prevent dehydration.,Do not eat any solid food while taking the preparation; only clear liquids are allowed.,Expect frequent, watery stools; stay near a restroom.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLOVAGE vs ALCAINE, answered by our medical review team.
COLOVAGE is a Osmotic Laxative that works by COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.. ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLOVAGE and ALCAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLOVAGE is: 4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.. The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLOVAGE and ALCAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLOVAGE is classified as Category C. Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.